AU2022292722B2 - Anti-csp antibodies - Google Patents

Anti-csp antibodies Download PDF

Info

Publication number
AU2022292722B2
AU2022292722B2 AU2022292722A AU2022292722A AU2022292722B2 AU 2022292722 B2 AU2022292722 B2 AU 2022292722B2 AU 2022292722 A AU2022292722 A AU 2022292722A AU 2022292722 A AU2022292722 A AU 2022292722A AU 2022292722 B2 AU2022292722 B2 AU 2022292722B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022292722A
Other languages
English (en)
Other versions
AU2022292722A1 (en
Inventor
Daniel Eric EMERLING
Randal R. Ketchem
Shaun M. Lippow
Wayne Volkmuth
Katherine L. WILLIAMS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atreca Inc
Original Assignee
Atreca Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atreca Inc filed Critical Atreca Inc
Publication of AU2022292722A1 publication Critical patent/AU2022292722A1/en
Application granted granted Critical
Publication of AU2022292722B2 publication Critical patent/AU2022292722B2/en
Priority to AU2025220692A priority Critical patent/AU2025220692A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022292722A 2021-06-17 2022-06-16 Anti-csp antibodies Active AU2022292722B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025220692A AU2025220692A1 (en) 2021-06-17 2025-08-19 Anti-CSP antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163211820P 2021-06-17 2021-06-17
US63/211,820 2021-06-17
PCT/US2022/033877 WO2022266383A1 (en) 2021-06-17 2022-06-16 Anti-csp antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025220692A Division AU2025220692A1 (en) 2021-06-17 2025-08-19 Anti-CSP antibodies

Publications (2)

Publication Number Publication Date
AU2022292722A1 AU2022292722A1 (en) 2024-01-04
AU2022292722B2 true AU2022292722B2 (en) 2025-05-22

Family

ID=84526612

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022292722A Active AU2022292722B2 (en) 2021-06-17 2022-06-16 Anti-csp antibodies
AU2025220692A Pending AU2025220692A1 (en) 2021-06-17 2025-08-19 Anti-CSP antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025220692A Pending AU2025220692A1 (en) 2021-06-17 2025-08-19 Anti-CSP antibodies

Country Status (9)

Country Link
US (2) US11655290B2 (cg-RX-API-DMAC7.html)
EP (1) EP4355774A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024524895A (cg-RX-API-DMAC7.html)
KR (1) KR20240047964A (cg-RX-API-DMAC7.html)
CN (1) CN117940450A (cg-RX-API-DMAC7.html)
AU (2) AU2022292722B2 (cg-RX-API-DMAC7.html)
IL (1) IL309422A (cg-RX-API-DMAC7.html)
MX (1) MX2023014984A (cg-RX-API-DMAC7.html)
WO (1) WO2022266383A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322413A (en) * 2023-02-03 2025-09-01 Atreca Inc Variants of anti-CSP antibody
WO2025194069A1 (en) * 2024-03-15 2025-09-18 Atreca, Inc. Anti-csp antibody variants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180362628A1 (en) * 2016-03-21 2018-12-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
WO2020172220A1 (en) * 2019-02-19 2020-08-27 Atreca, Inc. Anti-csp antibody variants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3954643B2 (ja) 1991-11-16 2007-08-08 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリア原虫由来のCSおよびHBsAG間のハイブリッド蛋白質
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
SG10201900183VA (en) * 2011-04-28 2019-05-30 Univ Leland Stanford Junior Identification of polynucleotides associated with a sample
KR20180029253A (ko) * 2015-07-22 2018-03-20 유레카 쎄라퓨틱스, 인코포레이티드 Psa 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180362628A1 (en) * 2016-03-21 2018-12-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
WO2020172220A1 (en) * 2019-02-19 2020-08-27 Atreca, Inc. Anti-csp antibody variants

Also Published As

Publication number Publication date
AU2022292722A1 (en) 2024-01-04
KR20240047964A (ko) 2024-04-12
US11655290B2 (en) 2023-05-23
MX2023014984A (es) 2024-03-12
EP4355774A4 (en) 2025-05-07
WO2022266383A1 (en) 2022-12-22
US12545723B2 (en) 2026-02-10
AU2025220692A1 (en) 2025-09-11
CN117940450A (zh) 2024-04-26
JP2024524895A (ja) 2024-07-09
NZ806561A (en) 2025-06-27
US20230167169A1 (en) 2023-06-01
IL309422A (en) 2024-02-01
EP4355774A1 (en) 2024-04-24
US20230002483A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
JP7331298B2 (ja) 抗体結合tslp及びその使用
US11440954B2 (en) Optimized anti-TL1A antibodies
JP7711079B2 (ja) Il4rに結合する抗体とその使用
TWI852077B (zh) 用於移除造血幹細胞的抗體藥物結合物
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
US10858434B2 (en) PD1 binding agents
TW201702264A (zh) 結合cd38之抗體治療劑
JP2015038109A (ja) 眼科疾患を治療する方法
EP3360896B1 (en) Antibody to hepatitis b surface antigen and use thereof
JP7538131B2 (ja) 抗cd79b抗体、その抗原結合フラグメントおよびそれらの医薬用途
US12545723B2 (en) Anti-CSP antibodies
AU2022262101A1 (en) Antibodies binding trop2 and uses thereof
JP7449390B2 (ja) 抗e-セレクチン抗体、組成物および使用の方法
WO2020221451A1 (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof
US20240166738A1 (en) Anti-tmem106b antibodies for treating and preventing coronavirus infections
US20220195023A1 (en) Anti-csp antibody variants
OA21630A (en) Anti-CSP antibodies.
WO2025194069A1 (en) Anti-csp antibody variants
JP2023520624A (ja) Ctla4に結合する抗体及びその使用
JP2023526294A (ja) Il6rに結合する抗体及びその使用
KR20260036054A (ko) 항-csp 항체 변이체
WO2025171256A1 (en) Compositions and methods for treating malaria
KR20240022546A (ko) 항il-36r 항체 및 그의 사용
HK40079597B (zh) 结合il4r的抗体及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)